688 results on '"Holdenrieder, Stefan"'
Search Results
102. Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer
103. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy
104. Developing a nationwide infrastructure for therapeutic drug monitoring of targeted oral anticancer drugs: the ON-TARGET study protocol
105. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy
106. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer
107. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer
108. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases
109. Circulating nucleosomes: a new addition to the personalized medicine toolkit
110. Time courses of HMGB1 and other inflammatory markers after generalized convulsive seizures
111. Interview: Noninvasive detection of colorectal cancer by nucleosomic markers
112. Diagnostic Potential of Exosomal microRNAs in Colorectal Cancer.
113. The Utility of Repetitive Cell-Free DNA in Cancer Liquid Biopsies.
114. Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study.
115. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy
116. Nucleosomes as a new prognostic marker in early cerebral stroke
117. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA
118. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients
119. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma
120. Tumour markers in prostate cancer: The post-prostate-specific antigen era.
121. Prognostic value of haemoglobin drop in patients with acute coronary syndromes.
122. Increased circulating cytokeratin 19 fragment levels in preterm neonates receiving mechanical ventilation are associated with poor outcome.
123. Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations.
124. DNA Integrity in Plasma and Serum of Patients with Malignant and Benign Diseases
125. Clinical Relevance of Circulating Nucleosomes in Cancer
126. Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® GI Monitor assay on the UniCel® DxI 800 Immunoassay System
127. Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® BR Monitor assay on the UniCel® DxI 800 Immunoassay System
128. Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® OV Monitor assay on the UniCel® DxI 800 Immunoassay System
129. Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy?
130. Nucleosomal DNA Fragments in Autoimmune Diseases
131. Early and Specific Prediction of the Therapeutic Efficacy in Non–Small Cell Lung Cancer Patients by Nucleosomal DNA and Cytokeratin-19 Fragments
132. Soluble MICA in malignant diseases
133. Nucleosomes in Serum of Patients with Early Cerebral Stroke
134. The prostate health index and the percentage of [-2]proPSA maintain their diagnostic performance when calculated with total and free PSA from different manufacturers.
135. Measurements of Complement Factor H-Related Protein (BTA-TRAK™ Assay) and Nuclear Matrix Protein (NMP22 Assay) — Useful Diagnostic Tools in the Diagnosis of Urinary Bladder Cancer?
136. Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific Enolase Enzyme Immunoassay
137. Circulating Nucleosomes in Serum
138. Creatine kinase and bleeding in patients with acute coronary syndromes.
139. Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis.
140. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial
141. Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy
142. 鳞状上皮细胞癌抗原水平新检测方法在宫颈癌、肺癌和头颈部癌鉴别诊断中的性能及临床表现
143. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients
144. Inhibition of Tumor–Host Cell Interactions Using Synthetic Heparin Mimetics.
145. The International Collaboration for Cancer Classification and Research.
146. Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments
147. A word of caution on using tumor biomarker reference change values to guide medical decisions and the need for alternatives.
148. Aspartate aminotransferase and mortality in patients with ischemic heart disease.
149. Preanalytical variables that affect the outcome of cell-free DNA measurements.
150. 一项在欧洲和中国进行的新型胃泌素释放肽前体(ProGRP)免疫检测多中心评估研究
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.